Inventor · disambiguated record
Ugur Sahin
Also filed as: SAHIN UGUR
199 granted patents·144 pending applications·1,154 citations·filing 1997–2025
99Inventor score
Files withBioNTech SE82BIONTECH AG40GANYMED PHARMACEUTICALS AG40SAHIN UGUR39BIONTECH RNA PHARMACEUTICALS GMBH26
Top patents by PatentIndex Score
343 records- 0198US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0298US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0398US7527933B2Genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2003·Granted May 5, 2009·115 cites·5 claims
- 0497US10808242B2Method for reducing immunogenicity of RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Oct 20, 2020·11 cites·7 claims
- 0596US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 0696US10106800B2Modification of RNA, producing an increased transcript stability and translation efficiencyBIONTECH AG·Filed 2016·Granted Oct 23, 2018·18 cites·11 claims
- 0795US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 0895US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 0995US8946388B2Monoclonal antibodies for treatment of cancerSAHIN UGUR·Filed 2009·Granted Feb 3, 2015·41 cites·16 claims
- 1095US8425902B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2008·Granted Apr 23, 2013·20 cites·3 claims
- 1195US8168427B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2006·Granted May 1, 2012·47 cites·5 claims
- 1294US11547673B1Coronavirus vaccineBioNTech SE·Filed 2021·Granted Jan 10, 2023·12 cites·45 claims
- 1394US10738355B2Individualized vaccines for cancerSAHIN UGUR·Filed 2012·Granted Aug 11, 2020·41 cites·25 claims
- 1494US10117918B2Antigen-specific T cell receptors and T cell epitopesSAHIN UGUR·Filed 2016·Granted Nov 6, 2018·18 cites·13 claims
- 1594US9751934B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Sep 5, 2017·13 cites·20 claims
- 1694US9476055B2Modification of RNA, producing an increased transcript stability and translation efficiencySAHIN UGUR·Filed 2006·Granted Oct 25, 2016·29 cites·19 claims
- 1794US8637012B2Genetic products differentially expressed in tumors and the use thereofSAHIN UGUR·Filed 2011·Granted Jan 28, 2014·18 cites·9 claims
- 1894US8586047B2Genetic products differentially expressed in tumors and the use thereofSAHIN UGUR·Filed 2009·Granted Nov 19, 2013·20 cites·18 claims
- 1994US8088588B2Genetic products differentially expressed in tumors and the use of thereofSAHIN UGUR·Filed 2008·Granted Jan 3, 2012·17 cites·13 claims
- 2093US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 2193US10717982B2Stabilization of poly(A) sequence encoding DNA sequencesBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2015·Granted Jul 21, 2020·18 cites·19 claims
- 2293US9718886B2Cancer therapy using CLDN6 target-directed antibodies in vivoSAHIN UGUR·Filed 2011·Granted Aug 1, 2017·13 cites·6 claims
- 2392US11878055B1Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 23, 2024·2 cites·30 claims
- 2492US11779659B2RNA constructs and uses thereofBioNTech SE·Filed 2021·Granted Oct 10, 2023·4 cites·22 claims
- 2592US9487584B2Antibodies specific for claudin 6 (CLDN6)SAHIN UGUR·Filed 2010·Granted Nov 8, 2016·19 cites·20 claims
- 2692US9321842B2Antibodies for treatment of cancerSAHIN UGUR·Filed 2012·Granted Apr 26, 2016·14 cites·30 claims
- 2792US9295717B2Vaccine composition comprising 5′-cap modified RNASAHIN UGUR·Filed 2010·Granted Mar 29, 2016·18 cites·16 claims
- 2892US9267177B2Identification of tumor-associated cell surface antigens for diagnosis and therapyBIONTECH AG·Filed 2015·Granted Feb 23, 2016·6 cites·7 claims
- 2991US11248264B2Individualized vaccines for cancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GGMBH·Filed 2020·Granted Feb 15, 2022·5 cites·19 claims
- 3091US10813996B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Oct 27, 2020·4 cites·18 claims
- 3191US10576146B2Particles comprising a shell with RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2018·Granted Mar 3, 2020·13 cites·15 claims
- 3291US9175088B2Identification of tumor-associated markers for diagnosing or monitoring ovarian cancerSAHIN UGUR·Filed 2010·Granted Nov 3, 2015·8 cites·14 claims
- 3391US7785801B2Identification of surface-associated antigens for tumor diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2005·Granted Aug 31, 2010·14 cites·4 claims
- 3490US10717780B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2018·Granted Jul 21, 2020·5 cites·12 claims
- 3590US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 3690US10155031B2Individualized vaccines for cancerBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2013·Granted Dec 18, 2018·12 cites·19 claims
- 3790US9770487B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 26, 2017·11 cites·30 claims
- 3890US9044382B2Genetic products differentially expressed in tumors and the use thereofTüreci Özlem·Filed 2005·Granted Jun 2, 2015·17 cites·7 claims
- 3990US6338947B1Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewithLUDWIG INST CANCER RES·Filed 2000·Granted Jan 15, 2002·33 cites·15 claims
- 4089US11925694B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Mar 12, 2024·1 cites·36 claims
- 4189US11559587B2RNA formulation for immunotherapyBioNTech SE·Filed 2019·Granted Jan 24, 2023·3 cites·44 claims
- 4289US11222711B2Predicting immunogenicity of T cell epitopesBioNTech SE·Filed 2014·Granted Jan 11, 2022·11 cites·34 claims
- 4389US10485884B2RNA formulation for immunotherapyBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2013·Granted Nov 26, 2019·16 cites·39 claims
- 4489US10053512B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Aug 21, 2018·6 cites·34 claims
- 4589US10017564B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·21 claims
- 4689US9512232B2Antibodies against Claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Dec 6, 2016·9 cites·11 claims
- 4789US9212228B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2012·Granted Dec 15, 2015·9 cites·42 claims
- 4888US10314890B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Jun 11, 2019·5 cites·40 claims
- 4988US2024117022A1Monoclonal antibodies against claudin-18 for treatment of cancerASTELLAS PHARMA INC·Filed 2023·Application pending·0 cites
- 5087US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
Showing the top 50 of 343 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ugur Sahin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →